ArticleHuman vaccines & immunotherapeutics2021
Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study.
Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 62 citations in OpenAlex.
- Distinct Humoral Response Development to Measles Virus Across Vaccine Platforms.The Journal of infectious diseases · 2026Article
- Seroprotection after measles vaccination in children with sickle cell anemia receiving hydroxyurea.Blood advances · 2026Observational
- Seroprevalence of IgG Antibodies to Measles, Mumps, Rubella and Varicella in Adolescents with Documented Two-Dose MMR Vaccination: Cross-Sectional Study.Antibodies (Basel, Switzerland) · 2026Article
- Sustaining herd immunity against measles: Insights from a serological cohort study in an outbreak-free population.Infection · 2026Article
- Informing quarantine policy for measles control in primary school and daycare settings: insights from a simulation study, Flanders, Belgium.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Why do we have a vaccine for measles, but not cytomegalovirus (CMV)?PLoS pathogens · 2026Article
- Decreasing Antibody Titers and the Slow Decay of Measles Immunity in Mexico's Current Epidemiological Landscape.Vaccines · 2026Article
- Epidemiological characteristics of childhood infectious diseases at Qingyang maternal and child health care hospital during the COVID-19 pandemic and the post-pandemic period.Frontiers in pediatrics · 2026Article
- Quantification of the IgG antibody response half-life for hybrid immunity to SARS-CoV-2.BMC medicine · 2025Article
- A commentary on measles vaccine in the context of outbreaks: Viral evolution, waning immunity and public trust.Human vaccines & immunotherapeutics · 2025Review
- Immune Response to Childhood Vaccination in Vertically Infected People Living with HIV: A Long-Term Evaluation.Vaccines · 2025Article
- The speed of vaccination rollout and the risk of pathogen adaptation.Journal of the Royal Society, Interface · 2025Article
- Achieving and sustaining measles elimination in Hong Kong, from 1967 to 2024: lessons to be learnt.BMJ global health · 2025Review
- Seroprevalence of Measles-, Mumps-, and Rubella-Specific Antibodies in Future Healthcare Workers in Serbia: A Cross-Sectional Study.Vaccines · 2025Article
- A Case Series of Adult Measles from a Tertiary Care Hospital in North India.The American journal of tropical medicine and hygiene · 2025Article
- Glycosylation as a strategic mechanism for measles virus and mumps virus immune evasion.Frontiers in immunology · 2025Review
- Epidemiological investigation of measles outbreak in a refugee settlement in Lamwo District, Uganda.The Pan African medical journal · 2025Article
- Unveiling immunity gaps and determining a suitable age for a third dose of the measles-containing vaccine: a strategic approach to accelerating measles elimination.The Lancet regional health. Southeast Asia · 2025Article
- Seronegative Vaccinees May Not Benefit From Multiple Booster Doses of MMR Vaccine in Restoring Immunity.Journal of medical virology · 2024Observational
- Individual and contextual factors associated with measles infection in Malaysia: a multilevel analysis.Osong public health and research perspectives · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The persistence of specific IgG after measles infection and after measles vaccination has not been sufficiently investigated. Current evidence suggests that immunity after the disease is life-long, whereas the response after two doses of measles-containing vaccine declines within 10-15 years. This study evaluated the proportion of individuals with detectable anti-measles IgG in two groups, those vaccinated with two doses of anti-MMR vaccine and those with a self-reported history of measles infection. Among the 611 students and residents who were tested, 94 (15%) had no detectable protective anti-measles IgG. This proportion was higher among vaccinated individuals (20%; GMT = 92.2) than among those with a self-reported history of measles (6%; GMT = 213.3;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.